Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6332-6341

  Rew, Yosup ^a   Sun, Daqing ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 232; ANTINEOPLASTIC AGENT; PIPERIDONE DERIVATIVE; UNCLASSIFIED DRUG; 2-(5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-(1-(ISOPROPYLSULFONYL)-3-METHYLBUTAN-2-YL)-3-METHYL-2-OXOPIPERIDIN-3-YL)ACETIC ACID; ACETIC ACID DERIVATIVE; PROTEIN BINDING; PROTEIN MDM2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NEOPLASM; NONHUMAN; OSTEOSARCOMA; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; PROTEIN CONFORMATION;

ACETATES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; HUMANS; MODELS, MOLECULAR; PIPERIDONES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84906087915     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500627s     Document Type: Article

References (37)

1. Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy Nat. Rev. Drug Discovery 2008, 7, 979-987
2. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network Nature (London) 2000, 408, 307-310
3. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 Mutations in human cancers Science (Washington, DC, U. S.) 1991, 253, 49-53
4. Soussi, T.; Dehouche, K.; Beroud, C. p53 Web-site and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis Hum. Mutat. 2000, 15, 105-113
5. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat. Rev. Cancer 2003, 3, 102-109
6. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas Nature (London) 1992, 358, 80-83
7. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 1992, 69, 1237-1245
8. Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K. W.; Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53 Nature (London) 1993, 362, 857-860
9. Roth, J.; Dobbelstein, M.; Freedman, D. A.; Shenk, T.; Levine, A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein EMBO J. 1998, 17, 554-564
10. Tao, W.; Levine, A. J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53 Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3077-3080
11. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. MDM2 promotes the rapid degradation of p53 Nature (London) 1997, 387, 296-299
12. Kubbutat, M. H. G.; Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability Mol. Cell. Biol. 1997, 17, 460-468
13. Vassilev, L. T. MDM2 inhibitors for cancer therapy Trends Mol. Med. 2007, 13, 23-31
14. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science (Washington, DC, U. S.) 2004, 303, 844-848
15. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B. T.; Qing, W.; Packman, K.; Myklebost, O.; Heimbrook, D. C.; Vassilev, L. T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 1888-1893
16. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Tomita, Y.; Parrish, D. A.; Deschamps, J. R.; Wang, S. Structure-based design of potent non-peptide MDM2 inhibitors J. Am. Chem. Soc. 2005, 127, 10130-10131
17. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2006, 49, 3432-3435
18. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3933-3938
19. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973
20. Rew, Y.; Sun, D.; Gonzalez-Lopez de Turiso, F.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B. M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.; Kopecky, D. J.; Li, Y.; Lo, M.-C.; Long, A. M.; Michelsen, K.; Oliner, J. D.; Osgood, T.; Ragains, M.; Saiki, A. Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Structure-based design of novel inhibitors of the MDM2-p53 interaction J. Med. Chem. 2012, 55, 4936-4954
21. Gonzalez-Lopez de Turiso, F.; Sun, D.; Rew, Y.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Correll, T. L.; Huang, X.; Julian, L. D.; Kayser, F.; Lo, M.-C.; Long, A. M.; McMinn, D.; Oliner, J. D.; Osgood, T.; Powers, J. P.; Saiki, A. Y.; Schneider, S.; Shaffer, P.; Xiao, S.-H.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Rational design and binding mode duality of MDM2-p53 inhibitors J. Med. Chem. 2013, 56, 4053-4070
22. Zhao, Y.; Yu, S.; Sun, W.; Liu, L.; Lu, J.; McEachern, D.; Shargary, S.; Bernard, D.; Li, X.; Zhao, T.; Zou, P.; Sun, D.; Wang, S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice J. Med. Chem. 2013, 56, 5553-5561
23. Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J.-J.; Zhao, C.; Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development ACS Med. Chem. Lett. 2013, 4, 466-469
24. Ding, Q.; Zhang, Z.; Liu, J.-J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X.-J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 2013, 56, 5979-5983
25. Zhang, Z.; Chu, X.-J.; Liu, J.-J.; Ding, Q.; Zhang, J.; Bartkovitz, D.; Jiang, N.; Karnachi, P.; So, S.-S.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L.; Graves, B. Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development ACS Med. Chem. Lett. 2014, 5, 124-127
26. Carry, J.-C.; Garcia-Echeverria, C. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic Bioorg. Med. Chem. Lett. 2013, 23, 2480-2485
27. Sun, D.; Li, Z.; Rew, Y.; Gribble, M.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chen, X.; Chow, D.; Deignan, J.; Duquette, J.; Eksterowicz, J.; Fisher, B.; Fox, B. M.; Fu, J.; Gonzalez, A. Z.; Gonzalez Lopez de Turiso, F.; Houze, J.; Huang, X.; Jiang, M.; Jin, L.; Kayser, F.; Liu, J. J.; Lo, M.-C.; Long, A. M.; Lucas, B.; McGee, L. R.; McIntosh, J.; Mihalic, J.; Oliner, J. D.; Osgood, T.; Peterson, M. L.; Roveto, P.; Saiki, A. Y.; Shaffer, P.; Toteva, M.; Wang, Y.; Wang, Y. C.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Yu, M.; Zhao, X.; Zhou, J.; Zhu, J.; Olson, S. H.; Medina, J. C. Discovery of AMG 232, a potent, selective, and orally bioavailable inhibitor of the MDM2-p53 interaction in clinical development J. Med. Chem. 2014, 57, 1454-1472
28. Allen, J. G.; Bourbeau, M. P.; Wohlhieter, G. E.; Bartberger, M. D.; Michelsen, K.; Hungate, R.; Gadwood, R. C.; Gaston, R. D.; Evans, B.; Mann, L. W.; Matison, M. E.; Schneider, S.; Huang, X.; Yu, D.; Andrews, P. S.; Reichelt, A.; Long, A. M.; Yakowec, P.; Yang, E. Y.; Lee, T. A.; Oliner, J. D. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction J. Med. Chem. 2009, 52, 7044-7053
29. Beck, H. P.; DeGraffenreid, M.; Fox, B.; Allen, J. G.; Rew, Y.; Schneider, S.; Saiki, A. Y.; Yu, D.; Oliner, J. D.; Salyers, K.; Ye, Q.; Olson, S. Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2752-2755
30. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science (Washington, DC, U. S.) 1996, 274, 948-953
31. Oxindole 2 is a diastereomer of MI-63 reported by Wang and co-workers (see ref 10b, Ding et al.). The stereochemistry and binding mode of inhibitor 2 were determined from in-house co-crystal structure (see ref 11b, Gonzalez-Lopez de Turiso et al.).
32. Ye, Q.; Jiang, B. M.; Chan, H.; Wong, K. B.; Jin, L. Optimization of hepatocyte intrinsic clearance assay for human metabolic clearance prediction: impact of assay conditions on prediction accuracy. Unpublished results.
33. Lucas, B. S.; Fisher, B.; McGee, L. R.; Olson, S. H.; Medina, J. C.; Cheung, E. An expeditious synthesis of the MDM2-p53 inhibitor AM-8553 J. Am. Chem. Soc. 2012, 134, 12855-12860
34. Canon, J.; Osgood, T.; Olson, S.; Saiki, A.; Robertson, R.; Bartberger, M.; Sun, D.; Ye, Q.; Jin, L.; Yu, D.; Ada Chen, A.; Zhou, J.; Cordover, D.; Kaufman, S.; Oliner, J.; Coxon, A.; Radinsky, R. The MDM2 inhibitor AMG 232 demonstrates robust anti-tumor activity and potentiates the activity of p53-inducing cytotoxic agents. Unpublished results.
35. El-Deiry, W. S.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression Cell 1993, 75, 817-825
36. Ye, Q.; Jiang, M.; Huang, W. T.; Ling, Y.; Olson, S. H.; Sun, D.; Xu, G.; Yan, X.; Jin, L. Pharmacokinetics and metabolism of AMG 232, a novel and orally bioavailable inhibitor of the MDM2-p53 interaction, in rat, dog, and monkey: in vitro-in vivo correlation. Unpublished results.
37. Wen, Z.; Martin, D. E.; Bullock, P.; Lee, K.-H.; Smith, P. C. Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences Drug Metab. Dispos. 2007, 35, 440-448